CooperCompanies lifts outlook after Q1 beat

CooperCompanies reported a solid start to fiscal 2026, posting first‑quarter revenue of $1.024 billion, an increase of 6% from the prior‑year period and about 3% organically. The medical device company’s results were driven by product launches, strong profitability and robust cash flow.

GAAP diluted earnings per share for the quarter were $0.66, up 27% from $0.52 a year earlier. Adjusted (non‑GAAP) diluted EPS rose 20% year over year to $1.10, compared with $0.92 last year, and exceeded analyst consensus of $1.03 by $0.07.

According to one report, the company’s earnings beat and raised outlook prompted a 4.7% rise in CooperCompanies’ share price. Other market data cited the stock trading at $80.20 during the day, down 2.2%, highlighting intraday volatility around the release.

CooperVision generated first‑quarter revenue of $695.1 million, up 8% from the prior year. Growth was supported by the continued strength of the premium MyDay contact lens portfolio and new product launches, including MyDay MiSight.

CooperSurgical delivered revenue of $329.0 million, a 3% year‑over‑year increase, with growth across both its Office and Surgical and Fertility businesses. Together, the segments contributed to steady gross margins of 68%, with a modest 60‑basis‑point decline on a non‑GAAP basis.

Operating margin improved to 21% from 19% a year ago, with non‑GAAP operating margin at 27%. Interest expense fell to $22.4 million from $26.0 million, supporting higher net income of $130.8 million compared with $104.3 million in the prior‑year quarter.

CooperCompanies generated free cash flow of $158.7 million in the first quarter, based on $260.9 million of cash provided by operations and $102.2 million of capital expenditures. Management cited strong cash generation as a factor in raising free cash flow guidance for the year.

During the quarter, the company repurchased approximately 1.1 million shares of common stock for $92.5 million at an average price of $82.04. CooperCompanies reported $873.9 million of remaining capacity under its share repurchase program.

As of the latest trading update, the company had a market capitalization of $15.65 billion, a debt‑to‑equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13, according to market data cited in the earnings coverage.

Following the first‑quarter performance, CooperCompanies raised its full‑year 2026 guidance. The company now expects total revenue between $4.306 billion and $4.346 billion, implying organic growth of 4.5% to 5.5%.

By segment, CooperVision revenue is projected at $2.906 billion to $2.932 billion with 4.5% to 5.5% organic growth, while CooperSurgical revenue is forecast between $1.400 billion and $1.413 billion, with 4.0% to 5.0% organic growth.

Non‑GAAP diluted EPS guidance was raised to a range of $4.58 to $4.66, above prior analyst consensus of $4.52, and the company now targets free cash flow of $600 million to $625 million for the fiscal year.

Research reports compiled around the time of the release indicate that Wall Street analysts maintain a “Moderate Buy” consensus rating on CooperCompanies, with an average price target of about $90.36. Individual firms have set price objectives ranging from the low‑$70s to the high‑$90s.

Recent disclosures show insider share purchases ahead of the quarter. CEO Albert G. White III bought 10,000 shares in December at an average price of $80.80 per share, while other executives and directors also added to their holdings. Over the last 90 days, insiders purchased 16,014 shares worth $1,304,416.

Institutional investors hold about 24.39% of the company’s stock, according to filings referenced in the earnings coverage, with several hedge funds and advisory firms increasing or initiating positions in recent quarters.